EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prognostic impact of post-chemoradiotherapy muscle quality in non-elderly adults with esophageal squamous cell carcinoma

Ling Xiao, Yu-Hang Yang, Shi-Chuan Zhang, Jia-Hua Lyu

World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)

DOI: 10.4251/wjgo.123400 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND Definitive chemoradiotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC); however, marked prognostic heterogeneity exists and simple predictive biomarkers are lacking. Although skeletal muscle density (SMD) reflects muscle quality, its posttreatment prognostic value and age-dependent modifying effect in ESCC remain unclear. AIM To explore the prognostic significance of post-treatment SMD (post-SMD) and to clarify the age-related interaction in patients with ESCC undergoing definitive chemoradiotherapy. METHODS Altogether, 255 eligible ESCC patients were retrospectively enrolled. Post-SMD was calculated using L3 vertebral-level abdominal computed tomography images. Additionally, multivariate logistic regression and restricted cubic spline were utilized to analyze the influencing factors and nonlinear age-post-SMD correlation. Moreover, survival analyses and Cox regression were performed to assess the prognostic value, followed by the construction and validation of an age-subgroup prognostic model. RESULTS In the entire cohort, lower post-SMD was significantly associated with worse survival (P = 0.034). A nonlinear relationship was identified between age and post-SMD, with 64 years established as the inflection point (P = 0.016). Consequently, the prognostic impact of post-SMD was highly age-dependent. It served as a significant predictor of poor survival exclusively in patients aged < 64 years (P = 0.020) but not in those ≥ 64 years (P = 0.439). Multivariate analysis confirmed that higher post-SMD was an independent protective factor for survival (hazard ratio = 0.633, P = 0.006). Based on these findings, we developed a prognostic model incorporating post-SMD specifically for patients under 64 years. This model demonstrated excellent performance in distinguishing high-risk patients (P < 0.001), exhibiting high discriminatory power [12-month area under the curve (AUC) = 0.820; 36-month AUC = 0.867], good calibration, and providing a positive net clinical benefit in decision curve analysis. CONCLUSION In this study cohort, post-SMD is a vital prognostic biomarker, and age acts as a core effect modifier in evaluating its prognostic significance. This finding can provide references for precise risk stratification and individualized management of the corresponding population.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →